This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome

This study has been completed.
University of Yaounde
Information provided by:
Gateway Health Alliance Identifier:
First received: March 25, 2008
Last updated: NA
Last verified: August 2006
History: No changes posted
The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.

Condition Intervention
Metabolic Syndrome Obesity Dyslipidemia Dietary Supplement: IGOB131

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.

Resource links provided by NLM:

Further study details as provided by Gateway Health Alliance:

Primary Outcome Measures:
  • Weight change [ Time Frame: 10 weeks ]

Secondary Outcome Measures:
  • Change in blood lipids and hormone levels [ Time Frame: 10 weeks ]

Enrollment: 102
Study Start Date: November 2006
Study Completion Date: April 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Compare active to placebo
Dietary Supplement: IGOB131
Comparison of 250 mg per day of Irvingia gabonensis to placebo

Detailed Description:

To assess the effects of seeds of Irvingia gabonensis on body weight, fasting blood glucose, plasma total and LDL cholesterol in 102 overweight and obese participants.

The study was a 10 week randomized, double blind, placebo controlled design. participants were randomly divided into 2 groups of 51 participants each. Group 1 was the placebo group, while Group 2 was the active group. Each group received 2 daily doses of 125 mg (before meals) of either placebo or Irvingia gabonensis.

Weight as well as fasting blood was taken at baseline and at 4, 8 and 10 weeks. No major detary changes or exercises were suggested during the study period.


Ages Eligible for Study:   19 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI>26

Exclusion Criteria:

  • Diabetics Pregnant and lactating Participating in any other weight reducing program Smokers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00645775

Laboratory of Nutrition & Nutritional Biochemistry
Yaounde, Centre, Cameroon, BP812
Sponsors and Collaborators
Gateway Health Alliance
University of Yaounde
Study Director: Julius E Oben, PhD Gateway Health Alliances / University of Yaounde
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Pr. Julius Oben, CSO, Gateway Health Alliances Identifier: NCT00645775     History of Changes
Other Study ID Numbers: GHAIGOB131CT
Study First Received: March 25, 2008
Last Updated: March 25, 2008

Keywords provided by Gateway Health Alliance:
Weight loss
Metabolic syndrome

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Nutrition Disorders
Body Weight
Signs and Symptoms
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Lipid Metabolism Disorders processed this record on September 21, 2017